FDA accepts Revolution Medicines NDA for daraxonrasib in pancreatic cancer
Tweet Send to a Friend
Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration accepted for review the company's New Drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


